Reinforcing these data, IHC and MELC staining demonstrated that tissues obtained from metastatic melanoma patients, which are known to have a worse prognosis, have higher expression levels of VEGFR‐3 and ANGPT2 compared with tissues obtained from patients with primary melanoma. This evidence concerns the gene FLT4 and metastatic melanoma.